Skip to Content
Merck
  • Understanding the Mechanism of Diabetes Mellitus in a LRBA-Deficient Patient.

Understanding the Mechanism of Diabetes Mellitus in a LRBA-Deficient Patient.

Biology (2022-04-24)
Iman Hawari, Johan Ericsson, Basirudeen Syed Ahamed Kabeer, Damien Chaussabel, Asma Alsulaiti, Sanaa A Sharari, Cristina Maccalli, Faiyaz Ahmad Khan, Khalid Hussain
ABSTRACT

The scope of this study is to show that DM in a LRBA-deficient patient with a stop codon mutation (c.3999 G > A) was not mediated through autoimmunity. We have evaluated the ability of the proband's T cells to be activated by assessing their CTLA-4 expression. A nonsignificant difference was seen in the CTLA-4 expression on CD3+ T cells compared to the healthy control at basal level and after stimulation with PMA/ionomycin. Blood transcriptomic analysis have shown a remarkable increase in abundance of transcripts related to CD71+ erythroid cells. There were no differences in the expression of modules related to autoimmunity diseases between the proband and pooled healthy controls. In addition, our novel findings show that siRNA knockdown of LRBA in mouse pancreatic β-cells leads reduced cellular proinsulin, insulin and consequently insulin secretion, without change in cell viability in cultured MIN6 cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-LRBA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab2